January 11, 2022
Kissei Pharmaceutical and Maruishi Pharmaceutical said on January 7 that their investigational agent difelikefalin (MR13A9) achieved the primary endpoint in a Japan PIII study for the treatment of pruritus in dialysis patients. The study enrolled 178 hemodialysis patients with previously...read more